This article was updated to note that the Decipher test is sold by Decipher Biosciences, not GenomeDx Biosciences.
NEW YORK – The National Comprehensive Cancer Network has updated prostate cancer guidelines to recommend biomarker testing for patients with unfavorable intermediate or high risk for aggressive disease.